Hyperprolactinemia (PRL, >15 ng/ml plasma)was observed in 70% of 73 patients with chronic renal failure (CRF) on maintenance hemodialysis. Plasma GH was also elevated (>5 ng/ml) in 42%, but PRL, GH, and creatinine levels did not correlate with one another. The MCR of human [131I]-PRL was determined in 6 normal females and 6 females with CRF using a constant infusion method. The PRL MCR was decreased by 33% in the CRF patients compared with that in normals (26.8 ± 2.3 vs. 40.2 ± 2.5 ml/min/m2; P < 0.01). The PRL secretion rate was 367 ±63 ng/min/m2 in the normals and 1162 ± 385 (P 131I]hPRL from plasma after discontinuation of the constantinfusion was multiexponential. The initial phase (0–45 min) disappearance rate was significantly prolonged (P < 0.01) in CRF patients. Sephadex G-75 gel filtration of plasma from a CRF patient obtained 30 min after a single injection of human [131I]PRL revealed that 94% of the immunoprecipitable radioactivity eluted in the position of the PRL monomer. Nearly all endogenous plasma PRL immunoreactivity in CRF patients also eluted as the PRL monomer. The disappearance of endogenous PRL from plasma during a dopamine infusion was compared in patients with CRF and control subjects. The impairment of the suppressive effects of dopamine in CRF patients could not be attributed solely to the decreased PRL MCR, suggesting the presence of decreased dopamine effectiveness. The results indicate that the hyperprolactinemia associated with CRF may be due, in part, to decreased PRL MCR but is primarily caused by an increase in PRL secretion. The lack of response to dopamine infusion in CRF patients suggests a lactotroph resistance to dopamine which may be a significant factor in the etiology of hyperprolactinemia associated with this disease.